The Alzheimer's Drug Discovery Foundation (ADDF) has made significant advances in advanced screening and prevention of the degenerative disorder over the last few years.
The organization had raised more than half of its funding from philanthropists with connections to companies like Microsoft (MSFT) - Get the Microsoft Corporation Report, Amazon (AMZN) - Get the Amazon.com Inc. Report, and Estee Lauder - 25 medical research projects aimed at early detection and proactive treatment strategies to fight Alzheimer's.
Nicolas Liponne/NurPhoto via Getty Images
Alzheimer's is expected to affect around 6 million people in the United States alone. The disease is detectable before side effects, thus about half of those who are living with Alzheimer's may not even realize they have it. This, according to researchers, makes the ADDF's effort in the field even more vital.
Bill Gates Protests ADDF's Success
The ADDF has two main objectives: to broaden the number of preventative therapy options for Alzheimer's, as well as to make testing for the illness more affordable and accessible. Current immunotherapy therapies are aimed at delaying the progression once the illness has become evident.
TheStreet Recommends It
This Holiday Season, Everything Will Be Coming to Disney Parks
Tesla Challenger Expands Sales Operations in the United States
The Oakland A's are in discussions for a stadium on the Las Vegas Strip near an iconic casino.
Alzheimer's patients are attempting to identify biomarkers that will make it simpler to diagnose which patients are predisposed to the illness. Since its founding, the ADDF has made significant progress in studying traits that might suggest trouble with Alzheimer's in the future.
Bill Gates has stated that the Diagnostic Accelerator for Alzheimer's is the future of treatment and prevention. Gates lost his own father to the disease in 2020, so he's acutely aware of the effect it can have on a family. The ADDF is at the cutting edge when it comes to identifying biomarkers for Alzheimer's.
Researchers in Seattle are using artificial intelligence to perform eye exams designed to uncover Alzheimer's predisposition in the brain, thereby making Alzheimer's prevention more accessible and convenient than ever.
Biogen and NFL players have joined the fray.
Bill Gates, Jeff Bezos, and Leonard A. Lauder, the co-heir to Estee Lauder's fortune, have all aided the ADDF in terms of financial stability. Over the last five years, the foundation has made many technological advances, including those mentioned above.
MacKenzie Scott, the Charles and Helen Schwab Foundation, and the American Frontotemporal Degeneration Association (AFD) have doubled their donations, from $50 million to a very impressive $100 million.These philanthropists will only see more exciting discoveries in the future.
With the ADDF, we launched the Diagnostics Accelerator to accelerate new research to find a simple yet reliable test to diagnose Alzheimer's early in its evolution. Thanks to the contributions of the funded researchers, there are now dozens of new biomarkers in the pipeline, crucial to advance new treatments for Alzheimer's and helping us better understand the condition.